Concepedia

Michael Melino

MM

Statistics

Publications

38

Citations

3.7K

H-Index

27

Active since

1981

Affiliations

Daiichi Sankyo (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of Alabama at Birmingham

University of Oklahoma

Center for Clinical Research (United States)

Michael Melino is an author at Daiichi Sankyo (United States) specializing in pharmacology, cardiovascular pharmacotherapy, and pharmacotherapy.

Publications per year

1981–2020

38

Publications

38

Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.

Francis J. Dumont, Mary Jo Staruch, Sam L. Koprak et al. · The Journal of Immunology · 1990 · 609 citations

Life Sciences, Immunology, Pharmacology +8

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

Claude Gagné, Harold Bays, Stuart Weiss et al. · The American Journal of Cardiology · 2002 · 495 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.

Francis J. Dumont, Michael Melino, Mary Jo Staruch et al. · The Journal of Immunology · 1990 · 355 citations · Full text

Life Sciences, Immunology, Pharmacology +16

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

Steven G. Chrysant, Michael Melino, Sulekha Karki et al. · Clinical Therapeutics · 2008 · 267 citations

Medicine, Pharmacology, Pharmacotherapy +13

Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?

N H Sigal, Francis J. Dumont, P. L. DURETTE et al. · The Journal of Experimental Medicine · 1991 · 249 citations · Full text

Medicine, Immunology, Pharmacology +13

1–5 of 38